MedTrace Logo

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

NCT03381625 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2021-10-05

No results posted yet for this study

Summary

This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice daily for up to 28 days.

Conditions

Interventions

DRUG

BMX-010

Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.

DRUG

Placebo

Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.

Sponsors & Collaborators

  • BioMimetix JV, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-02
Primary Completion
2021-07-24
Completion
2021-07-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03381625 on ClinicalTrials.gov